deucravacitinib vs zasocitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
deucravacitinib · Sotyktu
Marketed by Bristol-Myers Squibb
NCT03611751 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo- and active-controlled trial of 1,020 participants. Both primary clinical endpoints at week 16 were met: deucravacitinib produced significantly more participants with sPGA 0/1 and PASI 75 responses than placebo.
Next expected readout: November 2026 · NCT05570955 (registry estimate)
Reported efficacy
The Percentage of Participants With sPGA Response of 0 or 1 (At week 16); The Percentage of Participants With PASI 75 Response (At week 16): The Percentage of Participants With sPGA Response of 0 or 1 (At week 16): Arm 1: BMS-986165 55.6% (95% CI 47.4 to 63.7) vs Arm 2: Placebo 6.8% (95% CI 1 to 12.5) (met)
Result source: NCT04167462
zasocitinib
Developed by Takeda Pharmaceutical Company
NCT06108544 · Phase 3 · completed
This randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (n=1,108) in moderate-to-severe plaque psoriasis found that zasocitinib produced clear or almost-clear skin in 69.2% of patients at week 16, compared with 12.6% on placebo (p<0.001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: May 2027 · NCT07752108 (registry estimate)
Reported efficacy
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-100 at Week 16: LATITUDE Atlas, PASI 100 at week 16: more than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100), more than 2.5 times the response rate for deucravacitinib. (met)
Result source: NCT06973291
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | deucravacitinib | zasocitinib |
|---|---|---|
| PASI 75 | 53% vs 9.4%+43.6 vs placeboNCT036117519 other results
| 67.3% vs 5.8%+61.5 vs placeboNCT049998394 other results
|
| PASI 90 | 27% vs 2.7%+24.3 vs placeboNCT036117512 other results
| 46.2% vs 0%+46.2 vs placeboNCT049998393 other results
|
| PASI 100 | 10.2% vs 1.2%+9 vs placeboNCT036117512 other results
| 32.7% vs 0%+32.7 vs placeboNCT049998393 other results
|
| sPGA 0/1 | 49.5% vs 8.6%+40.9 vs placeboNCT0361175111 other results
| 51.9% vs 3.8%+48.1 vs placeboNCT049998395 other results
|
| DLQI, change | -10.2 vs -2.9−7.3 vs placeboNCT029318384 other results
| -8.9 vs -4.9−4 vs placeboNCT049998393 other results
|
PASI 75
- deucravacitinib
- 53% vs 9.4%+43.6 vs placeboNCT03611751
9 other results
- 58.4% vs 12.7% NCT03624127
- 68.8% vs 8.1% NCT04167462
- 53% vs 39.8% NCT03611751
- 58.4% vs 35.1% NCT03624127
- 75% vs 6.7% NCT02931838
- 66.7% vs 6.7% NCT02931838
- 9.1% vs 6.7% NCT02931838
- 38.6% vs 6.7% NCT02931838
- 68.9% vs 6.7% NCT02931838
- zasocitinib
- 67.3% vs 5.8%+61.5 vs placeboNCT04999839
4 other results
- 67.9% vs 5.8% NCT04999839
- 44.2% vs 5.8% NCT04999839
- 18% vs 5.8% NCT04999839
- 75.7% vs 12.1% NCT06088043
PASI 90
- deucravacitinib
- 27% vs 2.7%+24.3 vs placeboNCT03611751
2 other results
- 35.5% vs 4.2% NCT03624127
- 38.2% vs 1.4% NCT04167462
- zasocitinib
- 46.2% vs 0%+46.2 vs placeboNCT04999839
3 other results
- 45.3% vs 0% NCT04999839
- 21.2% vs 0% NCT04999839
- 8% vs 0% NCT04999839
PASI 100
- deucravacitinib
- 10.2% vs 1.2%+9 vs placeboNCT03611751
2 other results
- 14.2% vs 0.6% NCT03624127
- 4.2% vs 0% NCT04167462
- zasocitinib
- 32.7% vs 0%+32.7 vs placeboNCT04999839
3 other results
- 15.1% vs 0% NCT04999839
- 9.6% vs 0% NCT04999839
- 2% vs 0% NCT04999839
sPGA 0/1
- deucravacitinib
- 49.5% vs 8.6%+40.9 vs placeboNCT03611751
11 other results
- 53.6% vs 7.2% NCT03624127
- 55.6% vs 6.8% NCT04167462
- 49.5% vs 33.9% NCT03611751
- 53.6% vs 32.1% NCT03624127
- 75% vs 6.7% NCT02931838
- 64.4% vs 6.7% NCT02931838
- 20.5% vs 6.7% NCT02931838
- 38.6% vs 6.7% NCT02931838
- 75.6% vs 6.7% NCT02931838
- 35.5% vs 8.2% NCT05701995
- 51% vs 4.3% NCT05478499
- zasocitinib
- 51.9% vs 3.8%+48.1 vs placeboNCT04999839
5 other results
- 49.1% vs 3.8% NCT04999839
- 26.9% vs 3.8% NCT04999839
- 10% vs 3.8% NCT04999839
- 69.2% vs 12.6% NCT06108544
- 71.4% vs 10.7% NCT06088043
DLQI, change
- deucravacitinib
- -10.2 vs -2.9−7.3 vs placeboNCT02931838
4 other results
- -8.4 vs -2.9 NCT02931838
- -3.8 vs -2.9 NCT02931838
- -6.1 vs -2.9 NCT02931838
- -9.7 vs -2.9 NCT02931838
- zasocitinib
- -8.9 vs -4.9−4 vs placeboNCT04999839
3 other results
- -8.5 vs -4.9 NCT04999839
- -7.9 vs -4.9 NCT04999839
- -5.3 vs -4.9 NCT04999839
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. deucravacitinib: 4 of 4 rows · zasocitinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | deucravacitinib Rows use multiple source trials | zasocitinib Rows use multiple source trials |
|---|---|---|
| Dropout rate | 0.2%BMS-986165a NCT03611751 · Phase 3 · monotherapy show 20 more results—BMS-986165 (Week 0 up to Week 16) NCT03611751 · Phase 3 · monotherapy —BMS-986165 (Week 0 up to Week 52) NCT03611751 · Phase 3 · monotherapy 0%BMS-986165 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 16 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT03624127 · Phase 3 · monotherapy 9.6%Arm 1: BMS-986165 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 16 up to Week 52 NCT04167462 · Phase 3 · monotherapy —Active Treatment - Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence 0.8%Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05701995 · Phase 4 · registry result, not featured evidence —Active Treatment - Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence 8.7%Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05478499 · Phase 4 · registry result, not featured evidence 8.1%6 mg QD NCT03924427 · Phase 3 · registry result, not featured evidence 4.5%12 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 13.3%6 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 6.7%3 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 18.2%3 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 22.7%3 mg QOD NCT02931838 · Phase 2 · registry result, not featured evidence | 9.6%30 mga NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results13.2%15 mg NCT04999839 · Phase 2 · registry result, not featured evidence 13.5%5 mg NCT04999839 · Phase 2 · registry result, not featured evidence 16%2 mg NCT04999839 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —BMS-986165a NCT03611751 · Phase 3 · monotherapy show 20 more results—BMS-986165 (Week 0 up to Week 16) NCT03611751 · Phase 3 · monotherapy —BMS-986165 (Week 0 up to Week 52) NCT03611751 · Phase 3 · monotherapy —BMS-986165 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 16 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT03624127 · Phase 3 · monotherapy 2.7%Arm 1: BMS-986165 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 16 up to Week 52 NCT04167462 · Phase 3 · monotherapy —Active Treatment - Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05701995 · Phase 4 · registry result, not featured evidence —Active Treatment - Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence 3.9%Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05478499 · Phase 4 · registry result, not featured evidence 5.4%6 mg QD NCT03924427 · Phase 3 · registry result, not featured evidence 2.3%12 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 6.7%6 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 2.2%3 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 4.5%3 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 2.3%3 mg QOD NCT02931838 · Phase 2 · registry result, not featured evidence | 1.9%30 mga NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results1.9%15 mg NCT04999839 · Phase 2 · registry result, not featured evidence 1.9%5 mg NCT04999839 · Phase 2 · registry result, not featured evidence 2%2 mg NCT04999839 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —BMS-986165a NCT03611751 · Phase 3 · monotherapy show 20 more results1.6%BMS-986165 (Week 0 up to Week 16) NCT03611751 · Phase 3 · monotherapy 2.9%BMS-986165 (Week 0 up to Week 52) NCT03611751 · Phase 3 · monotherapy —BMS-986165 NCT03624127 · Phase 3 · monotherapy 2.1%BMS-986165 Week 0 up to Week 16 NCT03624127 · Phase 3 · monotherapy 5.8%BMS-986165 Week 0 up to Week 52 NCT03624127 · Phase 3 · monotherapy —Arm 1: BMS-986165 NCT04167462 · Phase 3 · monotherapy 2.7%BMS-986165 Week 0 up to Week 52 NCT04167462 · Phase 3 · monotherapy 0%BMS-986165 Week 16 up to Week 52 NCT04167462 · Phase 3 · monotherapy 4.9%Active Treatment - Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence 2.5%Placebo Controlled - Deucravacitin NCT05701995 · Phase 4 · registry result, not featured evidence 4.3%Active Treatment - Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence —Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence 1%Placebo Controlled - Deucravacitin NCT05478499 · Phase 4 · registry result, not featured evidence 6.8%6 mg QD NCT03924427 · Phase 3 · registry result, not featured evidence 0%12 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 0%6 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 2.2%3 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 2.3%3 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 2.3%3 mg QOD NCT02931838 · Phase 2 · registry result, not featured evidence | 0%30 mga NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results1.9%15 mg NCT04999839 · Phase 2 · registry result, not featured evidence 0%5 mg NCT04999839 · Phase 2 · registry result, not featured evidence 0%2 mg NCT04999839 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a nasopharyngitis 10.8% (placebo 11.4%) upper respiratory tract infection 4.9% (placebo 4.3%) diarrhoea 4.7% (placebo 7.5%) NCT03611751 · Phase 3 · monotherapy show 15 more resultsnasopharyngitis 16% (placebo 11.4%) upper respiratory tract infection 8.9% (placebo 4.3%) headache 5.4% (placebo 5.5%) NCT03611751 · Phase 3 · monotherapy nasopharyngitis 6.3% (placebo 4.2%) upper respiratory tract infection 6.3% (placebo 3.6%) headache 4.8% (placebo 3%) NCT03624127 · Phase 3 · monotherapy nasopharyngitis 18.1% (placebo 4.2%) upper respiratory tract infection 9.4% (placebo 3.6%) headache 6.6% (placebo 3%) NCT03624127 · Phase 3 · monotherapy upper respiratory tract infection 17.8% (placebo 18.9%) mouth ulceration 7.5% (placebo 5.4%) nasopharyngitis 6.8% (placebo 8.1%) NCT04167462 · Phase 3 · monotherapy psoriasis 11.8% (placebo 2.7%) headache 5.9% (placebo 0%) nasopharyngitis 5.9% (placebo 8.1%) NCT04167462 · Phase 3 · monotherapy covid-19 9.7% (placebo 4.1%) upper respiratory tract infection 7.8% (placebo 2%) nasopharyngitis 3.9% (placebo 4.1%) NCT05701995 · Phase 4 · registry result, not featured evidence acne 7.6% (placebo 4.1%) nasopharyngitis 6.7% (placebo 4.1%) covid-19 5.9% (placebo 4.1%) NCT05701995 · Phase 4 · registry result, not featured evidence nasopharyngitis 23.4% (placebo 17.8%) covid-19 12.8% (placebo 8.9%) upper respiratory tract infection 11.7% (placebo 6.7%) NCT05478499 · Phase 4 · registry result, not featured evidence nasopharyngitis 15.5% (placebo 17.8%) upper respiratory tract infection 11.7% (placebo 6.7%) acne 9.7% (placebo 2.2%) NCT05478499 · Phase 4 · registry result, not featured evidence 6 mg QD nasopharyngitis 31.1% acne 9.5% constipation 5.4% NCT03924427 · Phase 3 · registry result, not featured evidence 12 mg QD blood creatine phosphokinase increased 15.9% (placebo 2.2%) acne 9.1% (placebo 0%) diarrhoea 9.1% (placebo 4.4%) NCT02931838 · Phase 2 · registry result, not featured evidence 6 mg BID nasopharyngitis 15.6% (placebo 4.4%) blood creatine phosphokinase increased 8.9% (placebo 2.2%) upper respiratory tract infection 8.9% (placebo 2.2%) NCT02931838 · Phase 2 · registry result, not featured evidence 3 mg BID nasopharyngitis 11.1% (placebo 4.4%) aphthous ulcer 6.7% (placebo 0%) headache 6.7% (placebo 4.4%) NCT02931838 · Phase 2 · registry result, not featured evidence 3 mg QD nasopharyngitis 11.4% (placebo 4.4%) headache 9.1% (placebo 4.4%) psoriasis 6.8% (placebo 4.4%) NCT02931838 · Phase 2 · registry result, not featured evidence 3 mg QOD headache 9.1% (placebo 4.4%) nausea 9.1% (placebo 4.4%) blood immunoglobulin e increased 6.8% (placebo 2.2%) NCT02931838 · Phase 2 · registry result, not featured evidence | 30 mga covid-19 13.5% (placebo 1.9%) blood creatine phosphokinase increased 5.8% (placebo 3.8%) dermatitis acneiform 5.8% (placebo 0%) NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results15 mg covid-19 11.3% (placebo 1.9%) acne 5.7% (placebo 0%) blood creatine phosphokinase increased 5.7% (placebo 3.8%) NCT04999839 · Phase 2 · registry result, not featured evidence 5 mg covid-19 7.7% (placebo 1.9%) lymphocyte count decreased 5.8% (placebo 0%) blood creatine phosphokinase increased 3.8% (placebo 3.8%) NCT04999839 · Phase 2 · registry result, not featured evidence 2 mg covid-19 12% (placebo 1.9%) alanine aminotransferase increased 6% (placebo 0%) diarrhoea 6% (placebo 1.9%) NCT04999839 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
deucravacitinib
show 2 more results
show 2 more results
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 1 more result
+ 6 further endpoints in the CSV export.
Psoriatic Arthritis
Shared mechanism: TYK2 · full Psoriatic Arthritis pipeline
deucravacitinib · Sotyktu
Marketed by Bristol-Myers Squibb
NCT04908202 · Phase 3 · active, not recruiting
This was a large (670-patient), randomized, quadruple-blinded, placebo-controlled trial with the primary endpoint being ACR20 response, a validated hard clinical measure of joint disease activity. The result was statistically significant and favored deucravacitinib (54.2% vs 34.1% on placebo, p<0.0001), meeting all criteria for the highest evidence tier.
Next expected readout: December 2027 · NCT07280702 (registry estimate)
Reported efficacy
Number of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16: POETYK PsA-2 (NCT04908189), primary endpoint ACR20 at week 16: deucravacitinib 54.2% vs placebo 39.4%; p=0.0002 (met)
Result source: NCT04908189
zasocitinib
Developed by Takeda Pharmaceutical Company
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2027 · NCT06671496 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | deucravacitinib | zasocitinib |
|---|---|---|
| ACR20 | 52.9% vs 31.8%+21.1 vs placeboNCT038810591 other result
| 35.2% vs 29.2%+6 vs placeboNCT051531482 other results
|
| ACR50 | 24.3% vs 10.6%+13.7 vs placeboNCT038810591 other result
| 15.5% vs 9.7%+5.8 vs placeboNCT051531482 other results
|
| PASI 75 | 42.4% vs 20.4%+22 vs placeboNCT038810591 other result
| 25.6% vs 15.4%+10.2 vs placeboNCT051531482 other results
|
| Minimal disease activity | 22.9% vs 7.6%+15.3 vs placeboNCT038810591 other result
| 18.3% vs 12.5%+5.8 vs placeboNCT051531482 other results
|
| HAQ-DI, change | -0.4 vs -0.1−0.3 vs placeboNCT038810591 other result
| -0.3 vs -0.2−0.1 vs placeboNCT051531482 other results
|
ACR20
- deucravacitinib
- 52.9% vs 31.8%+21.1 vs placeboNCT03881059
1 other result
- 62.7% vs 31.8% NCT03881059
- zasocitinib
- 35.2% vs 29.2%+6 vs placeboNCT05153148
2 other results
- 53.3% vs 29.2% NCT05153148
- 54.2% vs 29.2% NCT05153148
ACR50
- deucravacitinib
- 24.3% vs 10.6%+13.7 vs placeboNCT03881059
1 other result
- 32.8% vs 10.6% NCT03881059
- zasocitinib
- 15.5% vs 9.7%+5.8 vs placeboNCT05153148
2 other results
- 26.7% vs 9.7% NCT05153148
- 26.4% vs 9.7% NCT05153148
PASI 75
- deucravacitinib
- 42.4% vs 20.4%+22 vs placeboNCT03881059
1 other result
- 59.6% vs 20.4% NCT03881059
- zasocitinib
- 25.6% vs 15.4%+10.2 vs placeboNCT05153148
2 other results
- 28.3% vs 15.4% NCT05153148
- 45.7% vs 15.4% NCT05153148
Minimal disease activity
- deucravacitinib
- 22.9% vs 7.6%+15.3 vs placeboNCT03881059
1 other result
- 23.9% vs 7.6% NCT03881059
- zasocitinib
- 18.3% vs 12.5%+5.8 vs placeboNCT05153148
2 other results
- 28% vs 12.5% NCT05153148
- 29.2% vs 12.5% NCT05153148
HAQ-DI, change
- deucravacitinib
- -0.4 vs -0.1−0.3 vs placeboNCT03881059
1 other result
- -0.4 vs -0.1 NCT03881059
- zasocitinib
- -0.3 vs -0.2−0.1 vs placeboNCT05153148
2 other results
- -0.3 vs -0.2 NCT05153148
- -0.3 vs -0.2 NCT05153148
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. deucravacitinib: 6 of 6 rows · zasocitinib: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | deucravacitinib | zasocitinib |
|---|---|---|
| ACR70 responder rate · % of participants | 14.3% (n=70) vs 1.5% (n=66) placebo @ 16wk6 mga,b,c,d NCT03881059 · Phase 2 · registry result, not featured evidence show 1 more dose19.4% (n=67) vs 1.5% (n=66) placebo @ 16wk12 mg NCT03881059 · Phase 2 · registry result, not featured evidence | 13.9% (n=72) vs 5.6% (n=72) placebo @ 12wka,b,c,d NCT05153148 · Phase 2 · registry result, not featured evidence show 2 more doses8.5% (n=71) vs 5.6% (n=72) placebo @ 12wk NCT05153148 · Phase 2 · registry result, not featured evidence 14.7% (n=75) vs 5.6% (n=72) placebo @ 12wk NCT05153148 · Phase 2 · registry result, not featured evidence |
| DAPSA absolute change · score | -23.2 vs -13.3 placebo score @ 16wk6 mga,b,c,d NCT03881059 · Phase 2 · registry result, not featured evidence show 1 more dose-25.6 vs -13.3 placebo score @ 16wk12 mg NCT03881059 · Phase 2 · registry result, not featured evidence | -16.79 vs -11.56 placebo score @ 12wka,b,c,d NCT05153148 · Phase 2 · registry result, not featured evidence show 2 more doses-15.3 vs -11.56 placebo score @ 12wk NCT05153148 · Phase 2 · registry result, not featured evidence -17.99 vs -11.56 placebo score @ 12wk NCT05153148 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 10%6 mge NCT03881059 · Phase 2 · registry result, not featured evidence show 7 more results—6 mg NCT03881059 · Phase 2 · registry result, not featured evidence —6 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence —6 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence 11.9%12 mg NCT03881059 · Phase 2 · registry result, not featured evidence —12 mg NCT03881059 · Phase 2 · registry result, not featured evidence —12 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence —12 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence | 21.1%NDI-034858 High Dosee NCT05153148 · Phase 2 · registry result, not featured evidence show 2 more results13.2%NDI-034858 Low Dose NCT05153148 · Phase 2 · registry result, not featured evidence 16.7%NDI-034858 Medium Dose NCT05153148 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 4.3%6 mge NCT03881059 · Phase 2 · registry result, not featured evidence show 7 more results—6 mg NCT03881059 · Phase 2 · registry result, not featured evidence —6 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence —6 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence 6%12 mg NCT03881059 · Phase 2 · registry result, not featured evidence —12 mg NCT03881059 · Phase 2 · registry result, not featured evidence —12 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence —12 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence | 6.6%NDI-034858 High Dosee NCT05153148 · Phase 2 · registry result, not featured evidence show 2 more results0%NDI-034858 Low Dose NCT05153148 · Phase 2 · registry result, not featured evidence 3.8%NDI-034858 Medium Dose NCT05153148 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —6 mge NCT03881059 · Phase 2 · registry result, not featured evidence show 7 more results7.7%6 mg NCT03881059 · Phase 2 · registry result, not featured evidence 0%6 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence 6.4%6 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence —12 mg NCT03881059 · Phase 2 · registry result, not featured evidence 0%12 mg NCT03881059 · Phase 2 · registry result, not featured evidence 0%12 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence 9.5%12 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence | 2.8%NDI-034858 High Dosee NCT05153148 · Phase 2 · registry result, not featured evidence show 2 more results5.6%NDI-034858 Low Dose NCT05153148 · Phase 2 · registry result, not featured evidence 4%NDI-034858 Medium Dose NCT05153148 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 6 mge aspartate aminotransferase increased 15.4% (placebo 0%) headache 15.4% (placebo 9.1%) hypertension 15.4% (placebo 0%) NCT03881059 · Phase 2 · registry result, not featured evidence show 5 more results6 mg QD bronchitis 10% (placebo 0%) diarrhoea 10% (placebo 0%) dizziness 10% (placebo 0%) NCT03881059 · Phase 2 · registry result, not featured evidence 6 mg QD headache 12.8% (placebo 9.1%) nasopharyngitis 12.8% (placebo 0%) bronchitis 6.4% (placebo 0%) NCT03881059 · Phase 2 · registry result, not featured evidence 12 mg pyrexia 18.8% (placebo 0%) alanine aminotransferase increased 12.5% (placebo 0%) aphthous ulcer 12.5% (placebo 0%) NCT03881059 · Phase 2 · registry result, not featured evidence 12 mg QD blood pressure increased 11.1% (placebo 0%) dizziness 11.1% (placebo 0%) furuncle 11.1% (placebo 0%) NCT03881059 · Phase 2 · registry result, not featured evidence 12 mg QD nasopharyngitis 26.2% (placebo 0%) covid-19 11.9% (placebo 0%) rash 9.5% (placebo 0%) NCT03881059 · Phase 2 · registry result, not featured evidence | e nasopharyngitis 9.7% (placebo 4.2%) upper respiratory tract infection 9.7% (placebo 2.8%) aphthous ulcer 8.3% (placebo 0%) NCT05153148 · Phase 2 · registry result, not featured evidence show 2 more resultsupper respiratory tract infection 11.3% (placebo 2.8%) nasopharyngitis 8.5% (placebo 4.2%) rash 4.2% (placebo 0%) NCT05153148 · Phase 2 · registry result, not featured evidence nasopharyngitis 9.3% (placebo 4.2%) headache 8% (placebo 4.2%) rash 8% (placebo 0%) NCT05153148 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 16 weeks versus 12 weeks.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
deucravacitinib
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 1 more result
show 1 more result
+ 8 further endpoints in the CSV export.
zasocitinib
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: deucravacitinib's landscape · zasocitinib's landscape